Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kondo, Mineo
Iwahashi, Chiharu
Parachuri, Nikulaa
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Bandello, Francesco
Loewenstein, Anat http://orcid.org/0000-0002-7706-1165
Kuppermann, Baruch D.
Article History
Received: 29 August 2022
Revised: 3 September 2022
Accepted: 6 September 2022
First Online: 16 September 2022
Competing interests
: AS: Consultant: for Novartis, Allergan, Bayer and Intas. MK: Clinical Research: Alcon, Bayer, Hoya, Kowa, Novartis, Otsuka, Santen, Senju; Consultant: Chugai, Daicel, Novartis, Ono, Sanofi, Asahi-Kasei, Senju. CI: none. FB: Consultant: Allergan, Bayer, Boehringer Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. BDK: Clinical Research: Alimera, Allegro, Allergan, Apellis, Boehringer Ingelheim, Clearside, Genentech, GSK, Ionis, IvericBio, jCyte, Novartis, Regeneron; Consultant: Alimera, Allegro, Allergan, Eyebio, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics/Ripple Therapeutics, IvericBio, jCyte, Novartis, Regeneron, Revana, Theravance Biopharma. NK: none. NP: none.